SCHEDULE 13D/A: Logos Global Management LP Amends Stake in Olema Pharmaceuticals, Drops Below 5% Ownership Due to Share Dilution

Logos Global Management LP and affiliated entities have filed an amended Schedule 13D for Olema Pharmaceuticals, Inc., reporting a decrease in their beneficial ownership to 4.7% due to an increase in the Issuer's outstanding shares, while maintaining their investment for strategic purposes.

Summary

• Logos Global Management LP and its affiliates, including Logos Global Management GP LLC, Logos Opportunities GP LLC, Logos GP LLC, Arsani William, and Graham Walmsley, filed an Amendment No. 3 to their Schedule 13D regarding their beneficial ownership in Olema Pharmaceuticals, Inc.
• The reporting persons collectively beneficially own 3,208,875 shares of Olema Pharmaceuticals Common Stock, representing 4.7% of the class.
• This percentage is based on 68,333,065 shares of Common Stock outstanding as of March 13, 2025, as reported in Olema's Form 10-K for the fiscal year ended December 31, 2024.
• The decrease in percentage ownership below 5% is attributed to an increase in the total number of outstanding shares of Olema Pharmaceuticals, not a sale of shares by the reporting persons.
• The shares were acquired for investment purposes using working capital from various funds, totaling approximately $41,477,923.12.
• Graham Walmsley, one of the reporting persons, serves on Olema Pharmaceuticals' board of directors.
• The reporting persons intend to routinely monitor their investment and may engage in future transactions, including purchasing or selling additional shares, entering into hedging or derivative transactions, or pledging interests.
• They also reserve the right to communicate with other stockholders and industry participants, and may recommend actions to the Issuer's management, board, and stockholders, potentially involving significant corporate events.
• The reporting persons hold certain registration rights, including demand, piggyback, and S-3 rights, for approximately 23.7 million shares, allowing them to register and sell their shares under specific conditions.

Sentiment

Score: 5

Explanation: The filing is primarily a factual update on beneficial ownership due to dilution. While the decrease in percentage ownership is 'worse' for the investor's stake, it's a consequence of the company's share count increase, not necessarily a negative signal from the investor. The continued investment and board representation suggest ongoing interest.

Positives

• The reporting persons, including a board member, maintain a significant investment in the company, indicating continued confidence in Olema Pharmaceuticals.
• The investment is primarily for 'investment purposes,' suggesting a strategic, long-term view rather than immediate activist intent, although they reserve the right to recommend actions.
• The reporting persons hold valuable registration rights (demand, piggyback, and S-3), which could facilitate future liquidity for their substantial holdings.

Negatives

• The reporting persons' percentage ownership has decreased below 5% due to share dilution from an increase in the Issuer's outstanding shares, which could be a concern for existing shareholders as it reduces their proportional ownership.

Risks

• The reporting persons may purchase additional shares, sell existing shares, or engage in hedging/derivative transactions, which could introduce volatility or impact the stock price.
• They may recommend actions to the Issuer's management, board, and stockholders, potentially leading to significant corporate events such as mergers, consolidations, sales or acquisitions of assets, changes in control, or other changes in capitalization.
• The expiration of certain registration rights no later than three years after the Issuer's initial public offering or when shares can be sold under Rule 144 could affect the liquidity options for certain holders.

Future Outlook

The reporting persons state they will routinely monitor Olema Pharmaceuticals regarding a wide variety of factors affecting their investment considerations. They may take various actions regarding their holdings, including purchasing additional Common Stock, selling existing shares, entering into or unwinding hedging or other derivative transactions, or pledging their interests to obtain liquidity. Furthermore, they may communicate with other stockholders, industry participants, and interested parties about the Issuer, and may recommend actions to the Issuer's management, board of directors, and stockholders, which could potentially involve significant corporate events such as mergers, consolidations, sales or acquisitions of assets, changes in control, issuances, purchases, dispositions or pledges of securities, or other changes in capitalization.

Industry Context

This filing primarily details a change in beneficial ownership due to share dilution and the ongoing investment strategy of a specific institutional investor in a pharmaceutical company. It does not provide broad industry trends or competitive analysis. The continued significant investment and the presence of a board member from the investment group suggest an active, informed investment approach, which is common in the biotech and pharmaceutical sectors where strategic investments and board representation can be key for influencing company direction and protecting shareholder interests.

Corporate Governance

Stakeholder Impact

• Shareholders: The decrease in percentage ownership due to dilution could be perceived negatively, as it means existing shares represent a smaller portion of the company. The potential for the reporting persons to buy or sell shares, or recommend corporate actions, could impact share price and corporate strategy.
• Management/Board: The reporting persons, including a board member, may communicate with and recommend actions to management and the board, potentially influencing strategic decisions.

Next Steps

• Reporting persons will routinely monitor Olema Pharmaceuticals regarding various factors affecting their investment.
• Reporting persons may purchase additional Common Stock in the open market or privately.
• Reporting persons may sell all or part of their Common Stock holdings.
• Reporting persons may enter into or unwind hedging or other derivative transactions.
• Reporting persons may pledge their interests in Common Stock to obtain liquidity.
• Reporting persons may communicate with other stockholders, industry participants, and interested parties about the Issuer.
• Reporting persons may recommend actions to the Issuer's management, board of directors, and stockholders, potentially involving corporate events like mergers, consolidations, or changes in capitalization.

Key Dates

Recommendation

Keywords

Olema Pharmaceuticals, Logos Global Management, Schedule 13D, Beneficial Ownership, Share Dilution, Investment Management, SEC Filing, Common Stock, Registration Rights, Biotechnology Investment, Institutional Investor